Healthy Japanese
Conditions
Interventions
Sponsors
Pharma Foods International Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Japanese 2.Men or women 3.Adults 4.Healthy individuals
Exclusion criteria
Exclusion criteria: 1.Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2.Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3.Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, metabolic bone disorders, including osteoporosis and fractures, or any other chronic diseases 4.Individuals who are taking medications that affect the gastrointestinal system (including Kampo medicines) and/or supplements containing peptides or amino acids 5.Individuals who are allergic to medicines or foods related to the test product, particularly those allergic to eggs 6.Individuals whose BMI is less than 18.5 kg/m2 or 30 kg/m2 or more 7.Individuals who are undergoing exercise or alimentary therapy under medical supervision 8.Individuals who have a present condition or have a medical history of drug or alcohol dependence 9.Individuals who are undergoing treatment for psychiatric disorder (including depressive symptoms) or sleep disorder 10.Individuals who are pregnant, lactating, or planning to become pregnant during this study 11.Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 12.Individuals who are judged as ineligible to participate in this study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Qualitative analysis of low-molecular-weight compounds transferred into the bloodstream following the intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Quantitative analysis of low-molecular-weight compounds transferred into the bloodstream following the intervention, Proteome analysis(Comprehensive protein analysis), Metabolomic analysis(Comprehensive analysis of metabolites) | — |
Countries
Japan
Contacts
Public ContactSaki Shirako
Pharma Foods International Co., Ltd. R&D Department
Outcome results
None listed